Clinical Trial: Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy

U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07035821) titled 'Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy' on June 16.

Brief Summary: Breakthrough chemotherapy-induced vomiting (CIV) is defined as CIV occurring after adequate antiemetic prophylaxis. Olanzapine is recommended for the treatment of breakthrough CIV in children, without adequate evidence. We conducted an open-label, single-center, phase 3 randomized controlled trial comparing the safety and efficacy of olanzapine and metoclopramide for treating breakthrough CIV.

Study Start Date: July 01

Study Type: INTERVENTIONAL

Condition: Breakthrough Chemotherapy-Induced Vomiti...